Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz H, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A; Australasian Leukaemia and Lymphoma Group. Hughes TP, et al. Among authors: januszewicz h. Blood. 2008 Nov 15;112(10):3965-73. doi: 10.1182/blood-2008-06-161737. Epub 2008 Sep 3. Blood. 2008. PMID: 18768781 Free article. Clinical Trial.
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.
Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, Filshie R, Januszewicz H, Joske D, Mills A, Simpson D, Tam C, Taylor K, Watson AM, Wolf M, Grigg A. Lasica M, et al. Among authors: januszewicz h. Leuk Lymphoma. 2019 Jul;60(7):1796-1802. doi: 10.1080/10428194.2018.1551533. Epub 2019 Jan 11. Leuk Lymphoma. 2019. PMID: 30632843
Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
Mollee P, Arthur C, Hughes T, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, Seymour JF, Martin N, Shina S, Low C, Wright S, Rodwell R, Coulston J, Morton J, Blacklock H, Taylor D, Taylor KM. Mollee P, et al. Among authors: januszewicz h. Ann Oncol. 2004 Dec;15(12):1810-5. doi: 10.1093/annonc/mdh468. Ann Oncol. 2004. PMID: 15550587 Free article. Clinical Trial.
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, Dean J, Januszewicz H, Johnstone R, Neeson P, Dickinson M, Nichols J, Prince HM. Harrison SJ, et al. Among authors: januszewicz h. Blood. 2011 Dec 8;118(24):6274-83. doi: 10.1182/blood-2011-03-339879. Epub 2011 Sep 12. Blood. 2011. PMID: 21911830 Free article. Clinical Trial.
Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor.
Morton J, Mollee P, Taylor K, Grigg A, Durrant S, Moore D, Rodwell R, Eliadis P, Hutchins C, Williams B, Seeley G, Wright S, Kelly C, Rentoul A, Iland H, Atkinson K, Januszewicz H, Bunce I, Bashford J, Stewart C, Taylor D. Morton J, et al. Among authors: januszewicz h. Leuk Res. 1999 Feb;23(2):177-83. doi: 10.1016/s0145-2126(98)00143-x. Leuk Res. 1999. PMID: 10071133
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Prince HM, Regester G, Gates P, Jablonskis L, Seymour JF, Lillie K, West R, Wolf M, Januszewicz H, Belford D. Prince HM, et al. Among authors: januszewicz h. Biol Blood Marrow Transplant. 2005 Jul;11(7):512-20. doi: 10.1016/j.bbmt.2005.04.001. Biol Blood Marrow Transplant. 2005. PMID: 15983551 Free article.
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Hertzberg M, Matthews JP, Stone JM, Dubosq MC, Grigg A, Ellis D, Benson W, Browett P, Horvath N, Januszewicz H, Abdi E, Green M, Bonaventura A, Marlton P, Cannell P, Wolf M; ALLG. Hertzberg M, et al. Among authors: januszewicz h. Am J Hematol. 2014 May;89(5):536-41. doi: 10.1002/ajh.23684. Epub 2014 Feb 21. Am J Hematol. 2014. PMID: 24481640 Free article. Clinical Trial.
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C, Bashford J, Brighton T, Cannell P, Dunlop L, Durrant S, Enno A, Eliadis P, Gill D, Gillett A, Gottlieb D, Januszewicz H, Joshua D, Leahy M, Schwarer A, Taylor K; Australian Leukaemia Study Group. Bradstock K, et al. Among authors: januszewicz h. Leukemia. 2001 Sep;15(9):1331-8. doi: 10.1038/sj.leu.2402218. Leukemia. 2001. PMID: 11516093 Clinical Trial.
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
Biagi JJ, Herbert KE, Smith C, Abdi E, Leahy M, Falkson C, Wolf M, Januszewicz H, Seymour JF, Richards K, Matthews JP, Dale B, Prince HM. Biagi JJ, et al. Among authors: januszewicz h. Leuk Lymphoma. 2005 Feb;46(2):197-206. doi: 10.1080/10428190400014884. Leuk Lymphoma. 2005. PMID: 15621802 Clinical Trial.
26 results